Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Apoptosis is Scopus-indexed (Q1, CiteScore 12.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer.
Checked against the index lists dated .
ISSN 1360-8185Verify ISSN ↗1573-675XVerify ISSN ↗
Publisher: Springer
Cost to publish: About US$5,090 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 13 / 191 | 93rd | Q1 |
| Pharmacology | 24 / 328 | 92nd | Q1 |
| Clinical Biochemistry | 11 / 124 | 91st | Q1 |
| Biochemistry (medical) | 8 / 78 | 90th | Q1 |
| Cancer Research | 32 / 233 | 86th | Q1 |
| Cell Biology | 41 / 289 | 85th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1996–present, best quartile Q1, CiteScore 12.4.
Apoptosis is Q1 in Pharmaceutical Science (rank 13 of 191), Q1 in Pharmacology (rank 24 of 328) and Q1 in Clinical Biochemistry (rank 11 of 124), by CiteScore 2025. It is ranked in 6 subject areas in all.
Apoptosis is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 12.4, which places it in quartile Q1 at the 93rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.242, quartile Q1, with an H-index of 138.
The publisher lists an article processing charge of about US$5,090 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Apoptosis is published by Springer. Its print ISSN is 1360-8185 and its online ISSN is 1573-675X.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Apoptosis has an h-index of 150 and a 2-year mean of 6.23 citations per paper (OpenAlex). Its Scopus CiteScore is 12.4, quartile Q1. On 2-year citations it ranks #21 of 177 Scopus journals in Pharmaceutical Science.
Apoptosis published 139 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (75.8%), India (6.4%) and United States (2.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 23 retracted papers are recorded (6.8 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.